X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
Lead Product(s): QLS-215
Therapeutic Area: Genetic Disease Product Name: QLS-215
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2021
Details:
Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of Hereditary Angioedema.
Lead Product(s): QLS-215
Therapeutic Area: Genetic Disease Product Name: QLS-215
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Quellis Biosciences Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 29, 2021
Details:
Through the acquisition, Catabasis strengthens its pipeline by including QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of Hereditary Angioedema.
Lead Product(s): QLS-215
Therapeutic Area: Genetic Disease Product Name: QLS-215
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Perceptive Advisors
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 29, 2021
Details:
Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent compared to placebo.
Lead Product(s): Edasalonexent
Therapeutic Area: Genetic Disease Product Name: CAT-1004
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
The posters include new preclinical research findings supporting potential positive effects on cardiac function and preservation of bone health with edasalonexent in mouse models of DMD.
Lead Product(s): Edasalonexent
Therapeutic Area: Genetic Disease Product Name: CAT-1004
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The agreements aims at assessing CAT-5571 as a potential oral therapy to promote autophagy and clear persistent lung infections in patients with both drug-sensitive and drug-resistant tuberculosis (TB).
Lead Product(s): CAT-5571
Therapeutic Area: Infections and Infectious Diseases Product Name: CAT-5571
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Medical Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 04, 2020
Details:
Catabasis Pharmaceuticals will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the Parent Project Muscular Dystrophy (PPMD) Virtual Annual Conference.
Lead Product(s): Edasalonexent
Therapeutic Area: Genetic Disease Product Name: CAT-1004
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The posters provide an overview of the baseline status of patients involved in PolarisDMD Ph 3 trial, findings from the MoveDMD Ph 2 trial and effect of oral edasalonexent in both the clinical trials.
Lead Product(s): Edasalonexent
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Details:
Catabasis Pharmaceuticals to present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD).
Lead Product(s): Edasalonexent
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2020
Details:
Edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy, is the company's lead program.
Lead Product(s): Edasalonexent
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
